Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.